We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IDEXX Stock Gains Following the Acquisition of CoVet
Read MoreHide Full Article
Key Takeaways
IDEXX acquired CoVet, adding AI-native ambient listening and clinical workflow software to its ecosystem.
CoVet integration may deepen patient insights, support personalized communication and boost diagnostic use.
CoVet's multi-region footprint will extend IDEXX software reach through VetConnect PLUS and new geographies.
IDEXX Laboratories, Inc. (IDXX - Free Report) recently announced the acquisition of CoVetAI Inc. (CoVet), a leading and rapidly growing provider of AI-native ambient listening and clinical workflow software for veterinary practices. The acquisition of CoVet reinforces software and AI as strategic enablers of diagnostic insights, workflow efficiency and practice performance.
Financial terms of the transaction were not disclosed.
Predicting IDXX Stock Movement Following the News
Following the announcement, IDXX’s shares edged up 0.6%, finishing at $513.62 yesterday.
IDEXX's software ecosystem continues to complement its diagnostics franchise by improving practice workflows and creating additional opportunities to integrate testing into clinical protocols. We expect the latest acquisition to further boost positive market sentiment for IDEXX stock in the coming days.
IDEXX has a market capitalization of $40.24 billion. The company’s earnings yield of 2.9% compares favorably to the industry’s negative 1.7%. In the trailing four quarters, it delivered an average earnings surprise of 5.7%.
Significance of the Acquisition
CoVet will be integrated into the IDEXX software ecosystem, which will continue to support other ambient scribe solutions and third-party integrations. CoVet will also continue to integrate with non-IDEXX practice management systems. Combined with IDEXX software, diagnostics, clinical decision support tools and solutions such as the Vello Client Engagement Platform, CoVet creates opportunities for deeper integration of patient information before, during and after the clinical visit.
Over time, these capabilities can help increase diagnostic utilization by surfacing relevant patient insights at key clinical decision points, supporting more personalized client communication and boosting capacity to see more patients.
CoVet's multi-region footprint also expands and enhances the global impact of IDEXX's software through integration with IDEXX VetConnect PLUS and by addressing practice team needs in geographies not currently served by IDEXX's practice management systems.
Image Source: Zacks Investment Research
Industry Prospects Favor IDEXX
Per a Grand View Research report, the global veterinary AI diagnostics market size was valued at $652.2 million in 2024 and is projected to grow from $849.4 million in 2026 to $2,633.8 million by 2033, at a CAGR of 17.2% during the period.
The market is being propelled by factors such as the rapid digital transformation of veterinary workflows, a surge in animal health data & connectivity, the use of advanced AI algorithms enabling precision diagnostics and the growing demand for early detection & preventive care in animals.
Another Recent Development by IDEXX
IDEXX launched the Catalyst proBNP Test, the first and only dual-species, in-clinic test for NT-proBNP, expanding cardiac capabilities across its connected point-of-care and reference laboratory portfolio. The test measures a well-established biomarker used to evaluate heart disease in companion animals. Catalyst proBNP brings laboratory-level accuracy and real-time cardiac assessment into routine workflows, whether used alone or alongside other chemistry tests.
IDXX Stock Price Performance
Over the past year, IDXX’s shares have dipped 19.8% compared with the industry’s 0.6% decline.
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 28.2% against the industry’s 3.8% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, sporting a Zacks Rank #1 at present, has an earnings yield of 6.7% against the industry’s negative 1.4% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 27.3% against the industry’s 3.8% decline over the past year.
Teleflex, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 14.5% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 4% against the industry’s 3.7% decline over the past year.
View the Zacks #1 Rank List
Image: Bigstock
IDEXX Stock Gains Following the Acquisition of CoVet
Key Takeaways
IDEXX Laboratories, Inc. (IDXX - Free Report) recently announced the acquisition of CoVetAI Inc. (CoVet), a leading and rapidly growing provider of AI-native ambient listening and clinical workflow software for veterinary practices. The acquisition of CoVet reinforces software and AI as strategic enablers of diagnostic insights, workflow efficiency and practice performance.
Financial terms of the transaction were not disclosed.
Predicting IDXX Stock Movement Following the News
Following the announcement, IDXX’s shares edged up 0.6%, finishing at $513.62 yesterday.
IDEXX's software ecosystem continues to complement its diagnostics franchise by improving practice workflows and creating additional opportunities to integrate testing into clinical protocols. We expect the latest acquisition to further boost positive market sentiment for IDEXX stock in the coming days.
IDEXX has a market capitalization of $40.24 billion. The company’s earnings yield of 2.9% compares favorably to the industry’s negative 1.7%. In the trailing four quarters, it delivered an average earnings surprise of 5.7%.
Significance of the Acquisition
CoVet will be integrated into the IDEXX software ecosystem, which will continue to support other ambient scribe solutions and third-party integrations. CoVet will also continue to integrate with non-IDEXX practice management systems. Combined with IDEXX software, diagnostics, clinical decision support tools and solutions such as the Vello Client Engagement Platform, CoVet creates opportunities for deeper integration of patient information before, during and after the clinical visit.
Over time, these capabilities can help increase diagnostic utilization by surfacing relevant patient insights at key clinical decision points, supporting more personalized client communication and boosting capacity to see more patients.
CoVet's multi-region footprint also expands and enhances the global impact of IDEXX's software through integration with IDEXX VetConnect PLUS and by addressing practice team needs in geographies not currently served by IDEXX's practice management systems.
Image Source: Zacks Investment Research
Industry Prospects Favor IDEXX
Per a Grand View Research report, the global veterinary AI diagnostics market size was valued at $652.2 million in 2024 and is projected to grow from $849.4 million in 2026 to $2,633.8 million by 2033, at a CAGR of 17.2% during the period.
The market is being propelled by factors such as the rapid digital transformation of veterinary workflows, a surge in animal health data & connectivity, the use of advanced AI algorithms enabling precision diagnostics and the growing demand for early detection & preventive care in animals.
Another Recent Development by IDEXX
IDEXX launched the Catalyst proBNP Test, the first and only dual-species, in-clinic test for NT-proBNP, expanding cardiac capabilities across its connected point-of-care and reference laboratory portfolio. The test measures a well-established biomarker used to evaluate heart disease in companion animals. Catalyst proBNP brings laboratory-level accuracy and real-time cardiac assessment into routine workflows, whether used alone or alongside other chemistry tests.
IDXX Stock Price Performance
Over the past year, IDXX’s shares have dipped 19.8% compared with the industry’s 0.6% decline.
IDXX’s Zacks Rank & Key Picks
IDEXX currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Teleflex (TFX - Free Report) .
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 28.2% against the industry’s 3.8% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Globus Medical, sporting a Zacks Rank #1 at present, has an earnings yield of 6.7% against the industry’s negative 1.4% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 27.3% against the industry’s 3.8% decline over the past year.
Teleflex, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 14.5% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 4% against the industry’s 3.7% decline over the past year.